Ashvattha Therapeutics, Inc.

As promised, our Phase 2 data has delivered a transformative treatment option for patients with retinal disease. Patients, physicians and payers all benefit from this therapy. We hope to bring this to market as soon as possible. Thank you again to the patients, caregivers, study coordinators and physicians in this clinical program! #amd, #dme, #retinaldisease

Positive news on our Phase 2 open label study for wet AMD and DME. ?? > Migaldendranib therapy obviates or reduces the need for more invasive in-the-eye injections > Multiple?subcutaneous?doses safe and well-tolerated? > 69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes? > 67% reduction in anti-VEGF IVT treatment in fellow eyes of bilateral disease patients > Maintenance of BCVA and reduction of CST in these previously treated patients https://lnkd.in/gfRZcTsQ

Excited to share the work of Wathsala Liyanage (lead author, Hopkins Medicine) on dendrimer-enabled non-viral delivery of CRISPR-Cas9 gene-editing agents, with great transfection efficacy, neutral and with minimal toxicity @NanoToday - more to come! A shout out also to Gokul Kannan (Stanford, second author) for getting together with Wathsala during COVID and initiating key studies, showing that the dendrimer can carry something much bigger than itself, even the magical CRISPR-Cas9 enzyme, a major delivery need! The article can be found here: https://lnkd.in/eG_6-f9C

Time to Change the Treatment Paradigm - Less Needles in the Eye In 1995, we held a meeting at #Genentech with renown leaders in retinal ophthalmology. These physicians were against injecting #amd and #dme patients in the eye over safety concerns. Now, in 2025, we have an alternative - at-home subcutaneous administration once per month that treats both eyes, dramatically reducing the need for the need for needles in the eye without ocular OR systemic safety issues. Very exciting to be releasing the Phase 2 data on Saturday, Feb 8! Thanks Michael Singer and our investigators, coordinators and patients for helping us transform retinal disease treatments! https://lnkd.in/gQRA5WiC

Ashvattha is the first therapeutics platform to target and reprogram macrophage and microglia (two important immune cells) which are known to be responsible for neurological disorders to cancer, ophthalmic diseases to autoimmune disorders. We're excited to partner with Tribe Capital and Arjun Sethi for our $50M Series B extension. Thankful to Natural Capital for their support since our incubation and to all investors that have supported the company since 2019 - Plum Alley Ventures Company, Jim Momtazee, Sam Altman. Our founding team of Kannan Rangaramanujam, Sujatha Kannan, and CEO Jeffrey Cleland have found a small particle called a hydroxyl dendrimer which is the basis for this new class of drugs called Hydroxyl Dendrimer Therapeutics (HDTs) HDTs can cross tissue barriers and are precision drugs with little to no side effects. Ashvattha's drugs have been through four safety studies and three Phase 2a (human proof of concept) studies. Migaldendranib, an HDT in an open label Phase 2a (human patients) is safe and showing demonstrated reduction in treatment for people going blind with wet AMD and Diabetic Macular Edema. Patients can conveniently treat themselves at home without injections in the eye. Interim results for the trial will be released in February. Flurimedrimer, an HDT that images neuroinflammation in progressive MS patient is going through a Phase 2a which we hope will demonstrate it crosses the blood brain barrier and targets activated microglia. Interim results for the study will be available by June 2025. HDT OP-101 succeeded in a Phase 2a clinical trial for seriously ill COVID patients and was safe and effective showing significantly lower mortality. We are proud to have a backlog of over 32 HDTs that have been discovered at Ashvattha. Onward!

We are developing a radiopharmaceutical that targets TAM (tumor associate macrophage) without any targeting ligand. Thought that was impossible, think again. Because our radiopharmaceutical is an HDT (hydroxyl dendrimer therapeutic) it comes with minimum toxicity to patients. #oncology #cancer #radiopharm

Today, we had the privilege of hosting Dr. Kannan Rangaramanujam from John Hopkins University School of Medicine for a thought-provoking seminar on "Development and Translation of Cell-Targeted Systemic Nanomedicines." Dr. Kannan began by addressing a crucial challenge in brain tumor and brain disorders —the difficulty of crossing the blood-brain barrier—and highlighted why most drugs fail in this context. He delved into the critical role of glial cells and neuroinflammation in CNS disorders, sharing how his team targets glial cell responses to protect neurons from degeneration. He spoke about his innovative drug delivery platform: a 'neutral' hydroxyl dendrimer. He shared compelling animal model data showing how dendrimer-drug conjugates effectively reach target cells, opening doors to next-generation therapies. Dr. Kannan concluded by discussing plans to advance targeted therapies in India for heart disease, obesity, inflammatory disorders, brain disorders, and more. The session ended with an engaging Q&A, reflecting the audience’s keen interest in the topic. The session was followed by interactions with our startups and THSTI fellows currently visiting Venture Center. We are grateful to Dr. Kannan for his time, insights, and inspiring discussions. It was truly a privilege to learn from his expertise and vision. Premnath Venugopalan Manish Gore, Ph.D. Smita Kale Translational Health Science and Technology Institute (THSTI) Ashvattha Therapeutics, Inc. Nusrat Sanghamitra PhD Vaibhav Bhatia CyGenica Lamark Biotech Jayant Khandare Actorius Innovations and Research Pvt Ltd Wilmer Eye Institute, Johns Hopkins Medicine #cnsdisorders #bloodbrainbarrier #dendrimers #drugdelivery #neuroinflammation #cancer

Ashvattha's HDTs cross the blood brain barrier and target microglia. They also have demonstrated safety in human subjects with four healthy volunteer safety studies and two Phase 2 studies accomplished. In a COVID study for serious COVID patients, our HDT OP-101 showed NfL, a neurodegenerative biomarker, reducing to baseline. Onward! #neuroinflammation

Our candidate for #WetAMD and #DME is a first-in-class hydroxyl dendrimer tyrosine kinase inhibitor. Currently, people living with wet AMD and DME are treated with intravitreal anti-VEGF injections given in-office by retinal ophthalmologists. We are advancing our candidate as an at-home, subcutaneously administered maintenance treatment that we believe will extend the time between anti-VEGF treatments. Learn more about our candidate here: https://brnw.ch/21wJhv2

Nearly 90,000 people in the U.S. are diagnosed with #ParkinsonsDisease every year. With no cure currently available, patients depend on treatments for symptom management to survive. At Ashvattha, we are conducting #ClinicalTrials in patients with #neurodegenerative conditions including #ParkinsonsDisease to determine the uptake of our hydroxyl dendrimer (HD) imaging agent in regions of #neuroinflammation to support the use of this agent as a companion biomarker for one of our HD therapeutics. Learn more here: https://brnw.ch/21wJ8ci